BEDFORD, Mass., Oct. 1, 2014 /PRNewswire/ -- Hologic, Inc.
(NASDAQ: HOLX) is kicking off Breast Cancer Awareness Month with
the announcement that the Company's groundbreaking 3D mammography
exam, available on the Selenia Dimensions platform, will be
introduced to consumers today as Genius 3D Mammography. Hologic's
Genius 3D Mammography is the only 3D exam approved by the FDA as
clinically superior to traditional mammography.
To view the multimedia assets associated with this release,
please click
http://www.multivu.com/players/English/7254155-hologic-new-consumer-awareness-campaign-mammography-technology/
In its continued quest to advance the fight against breast
cancer, Hologic is also announcing that it recently installed its
2,000th 3D mammography system worldwide. Hologic 3D
systems are now installed in over 50 countries and all 50
states.
Stephen MacMillan, Hologic's
President and CEO, said, "We have achieved a significant milestone
with our 2,000th 3D mammography system installed worldwide. And
today we are setting a course for the future as we launch our
"Genius 3D Mammography" campaign, an awareness initiative aimed
directly at women. The campaign is designed to make it easier for
them to ask for and find the most accurate mammography exam
available. An exam that significantly increases invasive cancer
detection and reduces false-positive callbacks impacts
the lives of women throughout the world. Genius 3D Mammography
is possibly the single greatest breakthrough in breast cancer
detection in 30 years. Every woman deserves the most accurate
mammogram possible."
Hologic's Genius 3D Mammography is designed to allow doctors to
see masses and distortions associated with cancers more clearly
than traditional 2D mammography. In a large peer-reviewed study
published in the prestigious Journal of the American Medical
Association (JAMA), researchers reported that Hologic's 3D
technology detects 41% more invasive breast cancers while
significantly reducing anxiety-provoking callbacks due to false
alarms.1 The largest study of its kind, the JAMA study
involved over 450,000 exams, 139 doctors and 13 leading academic
and clinical sites all using Hologic's 3D mammography
technology.
Peter J. Valenti III, Division
President, Breast and Skeletal Health Solutions, said, "The new
campaign will focus on how a Genius 3D Mammogram means improved
early detection. And of course, early detection increases a woman's
chance of being cured. Our healthcare customers have been asking us
to help educate women on the amazing benefits of this technology –
so we are. We hope that women can easily remember the Genius name
so they can ask their doctor about it."
A team of women developed the Genius name and brand identity.
Several of the women leading the effort have been personally
touched by breast cancer, making the Genius campaign a professional
and personal endeavor.
"It is time for women to not only be aware of the benefits of 3D
mammography, but to also know that they have a choice in the type
of mammogram they have, including the brand of the mammography
exam," said Linda Greer, M.D.,
Medical Director for John C. Lincoln Breast Health and Research
Center and one of the authors of the JAMA publication. "Women are
aware of a lot of brands– everything from our food to our cars - so
it makes sense that women should care about the brand of their
mammogram. I am pleased that Hologic has undertaken the mission to
make women aware of the life-saving potential of their Genius 3D
Mammogram."
Genius 3D Mammography is available on the Hologic Selenia
Dimensions 3D system. Since 2011, over 8 million women in the U.S.
have benefited from Hologic's Genius 3D Mammography. For more
information, visit www.Genius3DMammography.com.
About Hologic's Genius 3D Mammography:
While digital
(2D) mammography is considered one of the most advanced breast
cancer screening technologies available today, it provides only a
two-dimensional picture of the breast. The breast is a
three-dimensional object composed of different structures, such as
blood vessels, milk ducts, fat, and ligaments. These structures,
which are located at different heights within the breast, can
overlap and cause confusion when viewed as a two-dimensional, flat
image. This confusion of overlapping tissue is a leading reason why
small breast cancers may be missed and normal tissue may appear
abnormal, leading to unnecessary call backs.
Hologic's Genius 3D Mammography exam has been shown in numerous
clinical studies to significantly increase the detection of
invasive breast cancers while simultaneously reducing recall rates
across all patient populations and breast densities. The technology
was approved for breast cancer screening and diagnosis in the U.S.
in February, 2011 and has been available in countries recognizing
the CE mark since 2008.
A Genius 3D Mammography site finder for locations in
the United States is available at
www.Genius3DMammography.com.
About Hologic, Inc.:
Hologic, Inc. is a leading
developer, manufacturer and supplier of premium diagnostic
products, medical imaging systems and surgical products. The
Company's core business units focus on diagnostics, breast health,
GYN surgical, and skeletal health. With a unified suite of
technologies and a robust research and development program, Hologic
is dedicated to The Science of Sure. For more information on
Hologic, visit www.hologic.com.
Hologic, 3D Mammography, Dimensions, Genius 3D Mammography,
Selenia and associated logos are trademarks and/or registered
trademarks of Hologic, Inc. and/or its subsidiaries in the
United States and/or other countries.
Forward-looking Statement Disclaimer:
This News Release may contain forward-looking information that
involves risks and uncertainties, including statements about the
use of Hologic's 3D mammography technology. There can be no
assurance these products will achieve the benefits described herein
and that such benefits will be replicated in any particular manner
with respect to an individual patient as the actual effect of the
use of the products can only be determined on a case-by-case basis
depending on the particular circumstances and patient in question.
Hologic expressly disclaims any obligation or undertaking to
release publicly any updates or revisions to any such statements
presented herein to reflect any change in expectations or any
change in events, conditions or circumstances on which any such
statements are based.
Contacts:
|
|
Marianne
McMorrow
|
Jim
Culley
|
Manager, Corporate
Communications
|
Senior Director,
Corporate Communications
|
(781)
999-7723
|
(302)
528-1312
|
marianne.mcmorrow@hologic.com
|
jim.culley@hologic.com
|
1 Friedewald SM, Rafferty EA, Rose SL, Durand MA,
Plecha DM, Greenberg JS, Hayes MK, Copit DS, Carlson KL, Cink TM,
Barke LD, Greer LN, Miller DP, Conant EF. Breast cancer
screening using tomosynthesis in combination with digital
mammography. JAMA. 2014 Jun 25;311(24):2499-507. doi:
10.1001/jama.2014.6095.
To view the multimedia assets associated with this release,
please click
http://www.multivu.com/players/English/7254155-hologic-new-consumer-awareness-campaign-mammography-technology/
SOURCE Hologic, Inc.